Invasive lobular breast carcinoma is a unique form of breast cancer that starts in the milk-producing glands and grows differently than other types, often forming lines of cells rather than distinct lumps. The treatment approach combines surgery, hormone therapy, and sometimes chemotherapy, tailored to each patient’s cancer characteristics and overall health.

Managing a Cancer That Grows Differently

When doctors talk about treating invasive lobular breast carcinoma, they focus on several key goals: removing the cancer completely, preventing it from coming back, and helping patients maintain the best possible quality of life. This type of breast cancer requires careful attention because it behaves differently from the more common ductal breast cancer. The cancer cells spread out in single-file lines through breast tissue rather than forming a solid mass, which influences how doctors plan treatment^[1].

Treatment decisions depend heavily on the stage of the disease—meaning how large the cancer is and whether it has spread to lymph nodes or other parts of the body. Doctors also consider the hormone receptor status (whether the cancer responds to hormones like estrogen), the patient’s age, overall health, and personal preferences. Most invasive lobular carcinomas are hormone receptor-positive, which means they respond well to treatments that block hormones^[2].

The medical community has established standard treatment approaches based on years of research and clinical guidelines. However, scientists are also exploring new therapies through clinical trials, testing innovative approaches that may improve outcomes for patients in the future. Understanding both established and emerging treatments helps patients and their families make informed decisions about care^[3].

Standard Treatment Approaches

Surgery remains the primary treatment for invasive lobular carcinoma. Patients typically undergo either breast-conserving surgery (also called lumpectomy or wide local excision) or mastectomy (removal of the entire breast). Breast-conserving surgery removes the cancer along with a margin of healthy tissue around it. However, because invasive lobular carcinoma sometimes grows in multiple areas within the breast, doctors may recommend mastectomy when the cancer is too widespread for breast-conserving surgery to be effective^[7].

For many patients who choose or require mastectomy, breast reconstruction is an option. This can be performed at the same time as the mastectomy or scheduled for a later date, depending on the patient’s overall treatment plan and preferences. During surgery, doctors often perform a sentinel lymph node biopsy, removing three to five lymph nodes from under the arm to check whether cancer has spread. If cancer is found in these nodes, additional lymph nodes may need to be removed^[8].

Hormone therapy (also called endocrine therapy) is a cornerstone of treatment for most invasive lobular carcinomas because they are usually hormone receptor-positive. These medications work by blocking the effects of estrogen on cancer cells or by lowering estrogen levels in the body. Common hormone therapy drugs include tamoxifen, which blocks estrogen receptors on cancer cells, and aromatase inhibitors (such as anastrozole, letrozole, and exemestane), which reduce estrogen production in postmenopausal women. Treatment typically continues for five to ten years, significantly reducing the risk of cancer recurrence^[14].

Chemotherapy involves using powerful drugs to kill cancer cells throughout the body. Not all patients with invasive lobular carcinoma need chemotherapy. Doctors typically recommend it for larger tumors, cancer that has spread to lymph nodes, or cases with concerning features. Chemotherapy is usually given in cycles over several months, either before surgery (called neoadjuvant chemotherapy) or after surgery (adjuvant chemotherapy). The specific drugs used depend on individual cancer characteristics^[7].

Radiation therapy uses high-energy beams to destroy any cancer cells that might remain after surgery. Most patients who have breast-conserving surgery receive radiation therapy to the remaining breast tissue to reduce the risk of cancer returning. The treatment typically involves daily sessions over several weeks. Some patients who have mastectomy also receive radiation, particularly if the cancer was large or had spread to lymph nodes^[8].

Side effects vary depending on the treatment type. Surgery can cause pain, swelling, and changes in breast sensation. Hormone therapy may cause hot flashes, joint pain, and bone thinning over time. Chemotherapy often leads to fatigue, nausea, hair loss, and increased infection risk, though these effects are temporary and resolve after treatment ends. Radiation can cause skin changes similar to sunburn in the treated area. Modern supportive care has greatly improved the management of these side effects^[14].

Emerging Treatments in Clinical Trials

While standard treatments remain effective for many patients, researchers are actively investigating new approaches specifically designed to target the unique biology of invasive lobular carcinoma. Clinical trials are research studies that test whether new treatments are safe and effective before they become widely available. These trials happen in phases, each with a specific purpose^[2].

Phase I trials primarily focus on safety, testing a new treatment in a small group of people to determine the appropriate dose and identify side effects. Phase II trials expand the study to more participants to assess whether the treatment works against the cancer and to further evaluate safety. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to determine which approach is more effective^[15].

One major focus of research involves understanding the loss of a protein called E-cadherin, which is characteristic of invasive lobular carcinoma. This protein normally helps cells stick together. Its loss causes cancer cells to grow in lines rather than lumps, contributing to the unique behavior of this cancer. Scientists are exploring treatments that target the molecular pathways affected by E-cadherin loss^[15].

Researchers are also investigating drugs that target specific gene mutations common in invasive lobular carcinoma. The PIK3CA gene is frequently mutated in this cancer type. PI3K inhibitors are a class of targeted therapy drugs designed to block the activity of proteins produced by mutated PIK3CA genes. Some of these inhibitors are being tested in clinical trials, with early results showing promise in slowing cancer growth in patients whose tumors carry these mutations. The treatment works by interfering with signals that tell cancer cells to grow and divide^[9].

CDK4/6 inhibitors represent another class of targeted drugs being studied for invasive lobular carcinoma. These medications block proteins called cyclin-dependent kinases 4 and 6, which cancer cells need to divide. When combined with hormone therapy, CDK4/6 inhibitors have shown effectiveness in treating hormone receptor-positive breast cancers, including invasive lobular carcinoma. Several of these drugs have already been approved for advanced breast cancer and continue to be studied in earlier disease stages^[19].

Scientists are also exploring improved imaging techniques and new biomarkers that could help detect invasive lobular carcinoma earlier and monitor treatment response more accurately. Because this cancer is difficult to see on standard mammograms, research into advanced breast MRI techniques and novel imaging agents could significantly improve diagnosis and treatment planning. Some studies are testing whether combining different imaging methods provides better information than any single test alone^[12].

Clinical trials for invasive lobular carcinoma are being conducted at major cancer centers throughout the United States, Europe, and other regions. Patients interested in participating should discuss options with their oncology team. Not everyone qualifies for every trial—eligibility depends on factors such as cancer stage, prior treatments received, overall health status, and specific molecular characteristics of the tumor. Many specialized centers now offer consultation services to help match patients with appropriate clinical trials^[2].

Most common treatment methods

• Surgery
  • Breast-conserving surgery (lumpectomy) removes the cancer and surrounding healthy tissue while preserving most of the breast
  • Mastectomy removes the entire breast and is recommended when cancer is found in multiple areas
  • Sentinel lymph node biopsy checks whether cancer has spread to lymph nodes under the arm
  • Breast reconstruction can be performed immediately or delayed to rebuild the breast shape after mastectomy
• Hormone therapy (Endocrine therapy)
  • Tamoxifen blocks estrogen receptors on cancer cells and is used in premenopausal and postmenopausal women
  • Aromatase inhibitors (anastrozole, letrozole, exemestane) reduce estrogen production in postmenopausal women
  • Treatment typically continues for five to ten years to prevent cancer recurrence
  • Most effective for hormone receptor-positive invasive lobular carcinomas
• Chemotherapy
  • Uses powerful drugs to destroy cancer cells throughout the body
  • Recommended for larger tumors or cancer that has spread to lymph nodes
  • Can be given before surgery (neoadjuvant) or after surgery (adjuvant)
  • Typically administered in cycles over several months
• Radiation therapy
  • Uses high-energy beams to eliminate remaining cancer cells after surgery
  • Usually required after breast-conserving surgery to reduce recurrence risk
  • May be recommended after mastectomy for larger cancers or lymph node involvement
  • Treatment typically involves daily sessions over several weeks
• Targeted therapy
  • CDK4/6 inhibitors block proteins needed for cancer cell division and are combined with hormone therapy
  • PI3K inhibitors target specific gene mutations found in some invasive lobular carcinomas
  • These treatments focus on molecular pathways that drive cancer growth
  • Many are being studied in clinical trials or are available for advanced disease